Hematology · Sickle Cell Disease · Thalassemia · Coagulopathy

Research Focus Areas in Sickle Cell Disease and Thalassemia

1. Clinical Outcome and Pathogenesis: Investigating the clinical manifestations and underlying pathogenic mechanisms of sickle cell disease and thalassemia.
2. Cerebral Vasculopathy: Focusing on the study of cerebral vascular complications in patients with sickle cell disease and thalassemia.
3. Biomarker Development: Identifying and validating biomarkers for improved diagnosis and prognosis in sickle cell disease.
4. Early Intervention Studies: Conducting research on early intervention strategies to enhance patient outcomes in both sickle cell disease and thalassemia.
5. Development of Curative Therapies: Exploring innovative approaches to develop curative treatments for sickle cell disease.

Research in Coagulopathy in Hematology and Intensive Care

1. Bleeding Assessment and Prevention: Clinical studies on strategies to prevent bleeding in thrombocytopenic patients at the hematology ward and intensive care.

Clinical Studies in Acute Leukemia

1. Novel Interventions: Local PI on clinical trials to assess new treatment modalities for patients with acute leukemia.

Bart Biemond is Professor in Medicine, in particular hemoglobinopathies and senior staff member at the Department of Hematology of Amsterdam UMC, where he is responsible for both benign and malignant hematology care. His expertise and research focus predominantly on sickle cell disease and thalassemia. As head of the Sickle Cell/Thalassemia Expert Center for adult patients, he has been instrumental in guiding clinical and pre-clinical studies, particularly in the area of vasculopathy associated with hemoglobinopathies. In addition,, Bart Biemond actively contributes to broader research initiatives on clinical studies to prevent bleeding in thrombocytopenic hematology and intensive care patients and is involved in clinical studies to improve outcome of patients with acute leukemia.

He is a member of the SCORE national research group and has played a foundational role in establishing a national database for hemoglobinopathies, which is currently under development. His involvement extends to the Dutch Hemoglobinopathy Working Group, comprising hematologists, pediatricians, laboratory specialists, and specialized nurses. In this capacity, he collaborates with various international experts to advance the understanding and treatment of these disorders within the Genomed4all and Synthema consortium.

As a medical advisor for the Dutch patient foundation for sickle cell disease and thalassemia, known as Oscar, Biemond's expertise provides critical guidance for patient care and advocacy. His academic contributions to the field are noteworthy, with over 90 peer-reviewed scientific papers published on hemoglobinopathies. Additionally, Biemond is committed to fostering the next generation of researchers in this field, as evidenced by his supervision of PhD students currently undertaking studies in hemoglobinopathies.

Activities

• Clinical Scientist and senior staff Staff member Department of Hematology
• Medical head Hemoglobinopathy Expertise Center
• Director stem cell pheresis program